Compounds and compositions as protease inhibitors

A compound of Formula (I):

• in which:
• R1 is a group of Formula (a):
• wherein within Formula (a):
• X1 is —C(O)—;
• R5 is hydrogen or as defined together with R9;
• R7 is hydrogen;
• R9 is (i) (C1-6)alkyl or
• R9 and R5 together with the carbon atom to which both R9 and R5 are attached form (C3-8)cycloalkylene or (C3-8)heterocycloalkylene;
• and
• R11 is —X4X5R18, wherein X4 is —C(O)—, X5 is a bond, —O— or —NR19— where R19 is hydrogen or (C1-6)alkyl and R18 is phenyl, wherein said phenyl ring is substituted by:
• (i) —R22 where R22 is hetero(C3-12)cycloalkyl(C0-6)alkyl wherein said heterocycloalkyl is comprised of one or more ring members selected from —N═, —NR—, —O—, —S— or —S(O)2 wherein R is (C1-6)alkyl, or
• (ii) —X3OR22, —X3NR22R23, —X3NR23C(O)R22, —X3NR23C(O)OR22, —X3NR23S(O)2R22, —X3S(O)2R22, —X3C(O)R22 or —X3NR23C(O)NR22R23, wherein X3 is (C1-6)alkylene, R22 is hetero(C3-12)cycloalkyl(C0-6)alkyl wherein said heterocycloalkyl is comprised of one or more ring members selected from —N═, —NR—, —O—, —S— or —S(O)2 wherein R is (C1-6)alkyl and R23 at each occurrence independently is hydrogen or (C1-6)alkyl;
• wherein within R11 any alicyclic or aromatic ring system present may be substituted further by 1 to 5 radicals independently selected from (C1-6)alkyl, (C1-6)alkylidene, cyano, halo, halo-substituted (C1-4)alkyl, nitro, —X3NR12R12, —X3NR12C(O)OR12, —X3NR12C(O)NR12R12, —X3NR12C(NR12)NR12R12, —X3OR12, —X3SR12, —X3C(O)OR12, —X3C(O)NR12R12, —X3S(O)2NR12R12, —X3P(O)(OR3)OR12, —X3OP(O)(OR3)OR12, —X3NR12C(O)R13, —X3S(O)R13, —X3S(O)2R13 and —X3C(O)R13, wherein X3 is (C1-6)alkylene, R12 at each occurrence independently is hydrogen, (C1-6)alkyl or halo-substituted (C1-3)alkyl and R13 is (C1-6)alkyl or halo-substituted (C1-3)alkyl;
• R3 is hydrogen or as defined together with R4;
• and
• R4 is (i) hydrogen or
• R4 and R3 taken together with the carbon atom to which both R4 and R3 are attached form (C3-8)cycloalkylene or (C3-8)heterocycloalkylene, wherein said (C3-8)cycloalkylene or (C3-8)heterocycloalkylene optionally is substituted with (C1-6)alkyl;
• or
• a N-oxide derivative, individual stereoisomer or mixture of stereoisomers;
• or a pharmaceutically acceptable salt thereof.

A compound which is selected from a group consisting of:

• N-[1-(cyanomethyl-carbamoyl)-3-methyl-butyl]-3-[3-(3-morpholin-4-yl-propyl)-ureido]-benzamide;
• 4-dimethylamino-piperidine-1-carboxylic acid {4-[1-(cyanomethyl-carbamoyl)-3-methyl-butylcarbamoyl]-phenyl}-amide;
• and
• N-(1S-cyanomethylcarbamoyl-3-methylbutyl)-4-(4-methylpiperazin-1-yl)benzamide;
• and the N-oxide derivative, individual stereoisomer and mixture of stereoisomers;
• and the pharmaceutically acceptable salt thereof.